Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Animal Virus Infections Studies, and SARS-CoV-2 detection and testing.
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Defining the risk of SARS-CoV-2 variants on immune protection
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Systems vaccinology of the BNT162b2 mRNA vaccine in humans
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies
Activated human astrocyte‐derived extracellular vesicles modulate neuronal uptake, differentiation and firing